A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain

Biomedical Chromatography

Volumn 26, Issue 3, 2012, Pages 384-392

  Fortuna, Ana ^a,b   Alves, Gilberto ^b,c   Almeida, Anabela ^a,b   Lopes, Bruno ^a   Falcão, Amílcar ^a,b   Soares da Silva, Patrício ^d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^d DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Bioanalytical validation; Chiral liquid chromatography; Eslicarbazepine; Mouse plasma and brain; Oxcarbazepine

Indexed keywords

LIQUID CHROMATOGRAPHY; MAMMALS; PHASE SEPARATION; STEREOCHEMISTRY;

ANALYTES; BIOANALYTICAL; BIOANALYTICAL VALIDATION; CHIRAL LIQUID CHROMATOGRAPHY; CONCENTRATION RANGES; ESLICARBAZEPINE; MICE PLASMA; MOUSE BRAIN; OXCARBAZEPINE; SIMULTANEOUS DETERMINATIONS;

PHARMACOKINETICS;

BIA 2024; BIA 2059; BIA 2265; DIBENZAZEPINE DERIVATIVE; ESLICARBAZEPINE; LICARBAZEPINE; OXCARBAZEPINE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; SOLID PHASE EXTRACTION; ULTRAVIOLET RADIATION;

EID: 84856569184     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1670     Document Type: Article

References (30)

1. Almeida AM, Castel-Branco MM, Falcão AC. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. Journal of Chromatography B 2002; 774: 215-222.
2. Alves G, Figueiredo I, Castel-Branco M, Loureiro A, Falcão A, Caramona M. Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. Analytica Chimica Acta 2007a; 596: 132-140. doi: 10.1016/j.aca.2007.05.056.
3. Alves G, Figueiredo I, Castel-Branco M, Loureiro A, Fortuna A, Falcão A, Caramona M. Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomedical Chromatography 2007b; 21: 1127-1134; doi: 10.1002/bmc.858.
4. Alves G, Fortuna A, Falcão A. High-performance liquid chromatography and its impact in the development of chiral drugs: a review. Trends in Chromatography 2008a; 4: 1-10.
5. Alves G, Figueiredo I, Falcão A, Castel-Branco M, Caramona M, Soares-da-Silva P. Stereoselective disposition of S- and R-licarbazepine in mice. Chirality 2008b; 20: 796-804; doi: 10.1002/chir.20546.
6. Ambrósio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Research 2002; 27: 121-130.
7. Bohets H, Annaert P, Mannens G, Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K. Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 2001; 1: 367-383.
8. Budakova L, Brozmanova H, Grundmann M, Fischer J. Simultaneous determination of antiepelieptic drugs and their two active metabolites by HPLC. Journal of Separation Science 2008; 31: 1-8.
9. Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z. \The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Current Topics in Medicinal Chemistry 2001; 1: 353-366.
10. Carlson TJ, Fisher MB. Recent advances in high throughput screening for ADME properties. Combinatorial Chemistry and High Throughput Screening 2008; 11: 258-264.
11. Flesch G, Francotte E, Hell F, Degen PH. Determination of the R-(-) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. Journal of Chromatography 1992; 581: 147-151.
12. Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10, 11-dihydro-10-hydroxy carbamazepine. Epilepsy Research 2001; 44: 197-206.
13. Hainzl D, Loureiro AI, Parada A, Soares-da-Silva P. Metabolism of 10, 11-dihydro-10-hydroxyimino- 5H-dibenz/b, f/azepine-5-carboxamide, a potent anti-epileptic drug. Xenobiotica 2002; 32: 131-140; doi: 10.1080/00498250110087960.
14. Levert H, Odou P, Robert H. Simultaneous determination of four antiepileptic drugs in serum by high-performance liquid chromatography. Biomedical Chromatography 2002; 16: 19-24; doi: 10.1002/bmc.117.
15. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods 2000; 44: 235-249.
16. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports 2009; 61: 197-216.
17. Mazzucchelli I, Franco V, Marchiselli R, Perucca E, Gatti G. A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma. Therapeutic Drug Monitoring 2007; 29: 319-324.
18. Nef P. Key animal models for the identification and validation of drug targets. Drug Discovery Today 2001; 6: S91-S96.
19. Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfiels GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clinical Chemistry and Laboratory Medicine 2004; 42: 1228-1255; doi: 10.1515/CCLM.2004.245.
20. Parrot N, Paquereau N, Coassolo P, Lavé T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. Journal of Pharmaceutical Sciences 2005; 94: 2327-2342; doi: 10.1002/jps.20419.
21. Pauli I, Timmers LFSM, Caceres RA, Soares MBP, Azevedo WF. In silico and in vitro: identifying new drugs. Current Drug Targets 2008; 9: 1054-1061.
22. Pienimäki P, Fuchs S, Isojärvi J, Vähäkangas K. Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography. Journal of Chromatography B 1995; 673: 97-105.
23. Schmitt W, Willmann S. Physiology-based pharmacokinetic modeling: ready to be used. Drug Discovery Today: Technologies 2004; 1: 449-456; doi: 10.1016/j.ddtec.2004.09.006.
24. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
25. Sui X, Sun J, Wu X, Li H, Liu J, He Z. Predicting the volume of distribution of drugs in humans. Current Drug Metabolism 2008; 9: 574-580.
26. Tsaioun K, Bottlaender M, Mabondzo A. ADDME - avoiding drug development mistakes early: central nervous system drug discovery perspective. BMC Neurology 2009; 9: S1-S11; doi: 10.1186/1471-2377-9-S1-S1.
27. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available at:.
28. Volosov A, Yagen B, Bialer M. Comparative stereoselective pharmacokinetic analysis of 10- hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia 2000a; 41: 1107-1111.
29. Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A, Yagen B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10, 11-trans-dihydrodiol in human urine. Journal of Chromatography B 2000b; 738: 419-425.
30. Yengi LG, Leung L, Kao J. The evolving role of drug metabolism in drug discovery and development. Pharmaceutical Research 2007; 24: 842-858; doi: 10.1007/s11095-006-9217-9.